CR11454A - Derivados de isoxazolo-piridina - Google Patents

Derivados de isoxazolo-piridina

Info

Publication number
CR11454A
CR11454A CR11454A CR11454A CR11454A CR 11454 A CR11454 A CR 11454A CR 11454 A CR11454 A CR 11454A CR 11454 A CR11454 A CR 11454A CR 11454 A CR11454 A CR 11454A
Authority
CR
Costa Rica
Prior art keywords
isoxazolo
pyridine derivatives
pyridine
derivatives
isoxazol
Prior art date
Application number
CR11454A
Other languages
English (en)
Inventor
Bernd Buettelmann
Roland Jakob-Roetne
Henner Knust
Mathew C Lucca
Andrew Thomas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR11454A publication Critical patent/CR11454A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Abstract

La presente invencion se refiere derivados de isoxazol-piridina de la formula I en la que X, de R1, A R6 tienen los significados definidos en la reivindicacion 1.
CR11454A 2007-12-04 2010-05-21 Derivados de isoxazolo-piridina CR11454A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07122240 2007-12-04

Publications (1)

Publication Number Publication Date
CR11454A true CR11454A (es) 2010-06-28

Family

ID=40329314

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11454A CR11454A (es) 2007-12-04 2010-05-21 Derivados de isoxazolo-piridina

Country Status (34)

Country Link
US (6) US20090143371A1 (es)
EP (2) EP2767536B1 (es)
JP (1) JP5301557B2 (es)
KR (2) KR20120102117A (es)
CN (1) CN101889010B (es)
AR (1) AR069523A1 (es)
AU (1) AU2008333326B2 (es)
BR (1) BRPI0820112B8 (es)
CA (1) CA2707648C (es)
CL (1) CL2008003591A1 (es)
CO (1) CO6351788A2 (es)
CR (1) CR11454A (es)
CY (2) CY1116119T1 (es)
DK (2) DK2227467T3 (es)
EC (1) ECSP10010230A (es)
ES (2) ES2550994T3 (es)
HK (1) HK1149756A1 (es)
HR (2) HRP20150348T1 (es)
HU (1) HUE025545T2 (es)
IL (1) IL205759A (es)
MA (1) MA31865B1 (es)
MX (1) MX2010005717A (es)
MY (1) MY156747A (es)
NZ (1) NZ585308A (es)
PE (2) PE20091073A1 (es)
PL (2) PL2227467T3 (es)
PT (2) PT2767536E (es)
RS (2) RS53877B1 (es)
RU (1) RU2484091C2 (es)
SI (2) SI2767536T1 (es)
TW (1) TWI363624B (es)
UA (1) UA100132C2 (es)
WO (1) WO2009071476A1 (es)
ZA (1) ZA201003631B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2767536T1 (sl) 2007-12-04 2015-12-31 F. Hoffmann-La Roche Ag Derivati izoksazolo-piridina
EP2690095A1 (en) * 2008-10-21 2014-01-29 Camabay Therapeutics, Inc. Aryl gpr120 receptor agonists and uses thereof
US8748623B2 (en) 2009-02-17 2014-06-10 Syntrix Biosystems, Inc. Pyridinecarboxamides as CXCR2 modulators
US8389550B2 (en) * 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) * 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US8227461B2 (en) * 2009-04-30 2012-07-24 Hoffmann-La Roche Inc. Isoxazoles
CN102414205B (zh) * 2009-05-05 2014-11-05 弗·哈夫曼-拉罗切有限公司 异噁唑-吡唑衍生物
SG175869A1 (en) * 2009-05-05 2011-12-29 Hoffmann La Roche Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders
CN102414206B (zh) * 2009-05-05 2014-11-05 霍夫曼-拉罗奇有限公司 异*唑-吡啶衍生物
CN102414203B (zh) * 2009-05-07 2014-11-26 弗·哈夫曼-拉罗切有限公司 用作gaba调节剂的异*唑-吡啶衍生物
JP2013505297A (ja) * 2009-09-21 2013-02-14 ヴァンダービルト ユニバーシティー ｍＧｌｕＲ５の正のアロステリック調節因子としてのＯ−ベンジルニコチンアミド類似体
JP2013518129A (ja) 2010-01-28 2013-05-20 プレジデント アンド フェロウズ オブ ハーバード カレッジ プロテアソーム活性を向上させるための組成物および方法
CN103003265A (zh) 2010-07-19 2013-03-27 先正达参股股份有限公司 杀微生物剂
WO2012010567A1 (en) 2010-07-19 2012-01-26 Syngenta Participations Ag Isoxazole, isothiazole, furane and thiophene compounds as microbicides
JP6486002B2 (ja) * 2010-08-23 2019-03-20 シントリックス・バイオシステムズ・インコーポレイテッドＳｙｎｔｒｉｘ Ｂｉｏｓｙｓｔｅｍｓ， Ｉｎｃ． Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド
EP2457569A1 (en) 2010-11-05 2012-05-30 F. Hoffmann-La Roche AG Use of active pharmaceutical compounds for the treatment of central nervous system conditions
RU2563167C2 (ru) 2010-11-05 2015-09-20 Ф. Хоффманн-Ля Рош Аг Применение активных фармацевтических соединений для лечения заболеваний центральной нервной системы
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
US8604062B2 (en) 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
WO2013102142A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
EP2797597B1 (en) * 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
KR20150033679A (ko) 2012-06-26 2015-04-01 사니오나 에이피에스 페닐 트리아졸 유도체 및 이의 gabaa 수용체 복합체 조절용 용도
CA2876778A1 (en) 2012-06-26 2014-01-03 Saniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001280A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014150258A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
AP2015008722A0 (en) * 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EA034922B1 (ru) 2013-03-15 2020-04-07 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
SI3102208T1 (sl) 2014-02-07 2021-07-30 Global Blood Therapeutics, Inc. Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida
JP2017071553A (ja) * 2014-02-25 2017-04-13 味の素株式会社 ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
CN106810542B (zh) * 2015-11-30 2021-03-09 苏州开拓药业股份有限公司 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法
MX2018006832A (es) 2015-12-04 2018-11-09 Global Blood Therapeutics Inc Regimenes de dosificacion de 2-hidroxi-6-((2-(1-isopropil-1h-piraz ol-5-il)-piridin-3-il)-metoxi)-benzaldehido.
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
MX2019006696A (es) * 2016-12-08 2019-08-21 Hoffmann La Roche Nuevos derivados de isoxazolil eter como moduladores alostericos positivos (pam) de acido gamma-aminobutirico (gaba) a alfa5.
KR20200044906A (ko) * 2017-08-28 2020-04-29 유니버시티 오브 매릴랜드, 발티모어 기분장애를 위한 신규한 감마 아미노부티르산 타입 a 수용체 모듈레이터
WO2019122393A1 (en) * 2017-12-22 2019-06-27 Bayer Aktiengesellschaft Hydroxyisoxazolines and derivatives thereof
BR112020025355A2 (pt) 2018-06-13 2021-03-09 F. Hoffmann-La Roche Ag Derivados de éter de isoxazolila como gaba a alfa5 pam
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
US20240043418A1 (en) 2020-03-26 2024-02-08 Richter Gedeon Nyrt. 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
EP4334301A1 (en) 2021-05-05 2024-03-13 University College Cardiff Consultants Limited Heteroaryl compounds useful in the treatment of cognitive disorders
CN116854680A (zh) * 2022-03-28 2023-10-10 上海赛默罗生物科技有限公司 异噁唑-杂环类衍生物、药物组合物和用途
CN115286636A (zh) * 2022-10-08 2022-11-04 上海赛默罗生物科技有限公司 烟酰胺晶型及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812225A1 (de) * 1988-04-13 1989-10-26 Basf Ag Isoxazol(isothiazol)-5-carbonsaeureamide
WO2000008001A1 (en) 1998-08-07 2000-02-17 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
DE19920791A1 (de) * 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
GB0125086D0 (en) 2001-10-18 2001-12-12 Merck Sharp & Dohme Novel compounds
US20060148858A1 (en) 2002-05-24 2006-07-06 Tsuyoshi Maekawa 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity
GB0221443D0 (en) * 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
RU2408589C2 (ru) * 2004-05-14 2011-01-10 Айрм Ллк Соединения и композиции в качестве модуляторов ppar-рецепторов, активируемых пролифератором пероксисом
DE602005011318D1 (de) * 2004-10-01 2009-01-08 Hoffmann La Roche Hexafluorisopropanolsubstituierte etherderivate
WO2007002635A2 (en) * 2005-06-27 2007-01-04 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
DE602006003777D1 (de) * 2005-09-19 2009-01-02 Hoffmann La Roche Isoxazolderivate als inverse gaba a alpha5 agonisten
AU2006301376A1 (en) * 2005-10-11 2007-04-19 F. Hoffmann-La Roche Ag Isoxazole derivatives
KR101121240B1 (ko) * 2005-12-23 2012-06-12 에프. 호프만-라 로슈 아게 아릴-아이속사졸-4-일-옥사다이아졸 유도체
CA2633536A1 (en) 2005-12-27 2007-07-05 F. Hoffmann-La Roche Ag Aryl-isoxazol-4-yl-imidazo[1, 5-a]pyridine derivatives
CN101351461B (zh) 2005-12-27 2011-09-07 弗·哈夫曼-拉罗切有限公司 芳基-异*唑-4-基-咪唑衍生物
EP1979350A1 (en) 2006-01-17 2008-10-15 F.Hoffmann-La Roche Ag Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of alzheimer's disease via gaba receptors
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
SI2767536T1 (sl) * 2007-12-04 2015-12-31 F. Hoffmann-La Roche Ag Derivati izoksazolo-piridina
AU2008333320B2 (en) 2007-12-04 2012-12-20 F. Hoffmann-La Roche Ag Isoxazolo-pyrazine derivatives
US8227461B2 (en) * 2009-04-30 2012-07-24 Hoffmann-La Roche Inc. Isoxazoles

Also Published As

Publication number Publication date
CY1116902T1 (el) 2017-04-05
DK2767536T3 (en) 2015-10-19
PL2227467T3 (pl) 2015-05-29
BRPI0820112B1 (pt) 2019-01-15
WO2009071476A1 (en) 2009-06-11
ECSP10010230A (es) 2010-07-30
EP2227467A1 (en) 2010-09-15
PT2767536E (pt) 2015-11-17
IL205759A (en) 2014-07-31
TW200924763A (en) 2009-06-16
CY1116119T1 (el) 2017-02-08
CN101889010B (zh) 2012-12-05
JP5301557B2 (ja) 2013-09-25
SI2767536T1 (sl) 2015-12-31
EP2767536A1 (en) 2014-08-20
US8846719B2 (en) 2014-09-30
MX2010005717A (es) 2010-06-02
HRP20150348T1 (hr) 2015-05-08
AR069523A1 (es) 2010-01-27
PT2227467E (pt) 2015-03-02
KR20100075669A (ko) 2010-07-02
NZ585308A (en) 2012-03-30
PE20130242A1 (es) 2013-03-04
US20130274468A1 (en) 2013-10-17
BRPI0820112A2 (pt) 2015-05-05
PL2767536T3 (pl) 2016-01-29
CL2008003591A1 (es) 2010-01-04
KR101237576B1 (ko) 2013-03-04
ZA201003631B (en) 2013-10-30
MA31865B1 (fr) 2010-11-01
EP2227467B1 (en) 2014-12-31
US20120184538A1 (en) 2012-07-19
RU2484091C2 (ru) 2013-06-10
ES2550994T3 (es) 2015-11-13
EP2767536B1 (en) 2015-09-02
PE20091073A1 (es) 2009-07-23
US8877782B2 (en) 2014-11-04
US8877783B2 (en) 2014-11-04
CA2707648A1 (en) 2009-06-11
AU2008333326B2 (en) 2013-05-30
US9073908B2 (en) 2015-07-07
RS54355B1 (en) 2016-04-28
CN101889010A (zh) 2010-11-17
RU2010123923A (ru) 2012-01-10
AU2008333326A1 (en) 2009-06-11
ES2531023T3 (es) 2015-03-09
UA100132C2 (en) 2012-11-26
HK1149756A1 (en) 2011-10-14
JP2011505401A (ja) 2011-02-24
DK2227467T3 (en) 2015-01-19
US20130281690A1 (en) 2013-10-24
CO6351788A2 (es) 2011-12-20
US20130274469A1 (en) 2013-10-17
HRP20151250T1 (hr) 2015-12-18
TWI363624B (en) 2012-05-11
US8518974B2 (en) 2013-08-27
US20090143371A1 (en) 2009-06-04
RS53877B1 (en) 2015-08-31
CA2707648C (en) 2014-08-12
US20130274467A1 (en) 2013-10-17
MY156747A (en) 2016-03-31
KR20120102117A (ko) 2012-09-17
IL205759A0 (en) 2010-11-30
HUE025545T2 (en) 2016-03-29
BRPI0820112B8 (pt) 2021-05-25
SI2227467T1 (sl) 2015-03-31

Similar Documents

Publication Publication Date Title
CR11454A (es) Derivados de isoxazolo-piridina
UY39128A (es) Composiciones y métodos para modular la senda de señalización de wnt
CR11548A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
UY31562A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
UY31563A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
UY31560A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
UA107791C2 (en) Pesticidal compositions
CR20110635A (es) Quinazolinas sustituidas como fungicidas
EA201070519A1 (ru) Соединения тропана
DOP2012000038A (es) Conjugados de dímeros de pirrolo [1,4] benzodiazepina como agentes anticancerosos
CR11241A (es) Compuestos de pirazol y su uso como inhibidores de raf
BRPI0913806A2 (pt) "composição"
CU20120122A7 (es) Derivados 5-aril-1,2,4-triazolona ligada a bisarilo sustituidos
CR10027A (es) Nuevos derivados de pirrol fusionado
BRPI0914375A2 (pt) ''composições antiperspirantes''
ECSP088082A (es) Derivados de piridazina
UY31688A1 (es) Plaguicidas
SV2010003617A (es) Fungicidas
MA32647B1 (fr) Composés pyrrole
EA201070786A1 (ru) Бензофуропиримидиноны
SV2010003502A (es) Fungicidas novedosos
RS52255B (en) NALMEFEN HYDROCHLORIDE DIHYDRATE
GT201200084A (es) Antitransparente que reduce/elimina la decoloración amarilla en las prendas de vestir
CR20110220A (es) Arilciclohexiléteres de dihidro-tetraazabenzoazuleno
UA106880C2 (uk) Нові гербіциди